New antithrombotic agents in the ambulatory setting.

Area of Science:

• Pharmacology
• Cardiology
• Perioperative Medicine

Background:

• Increasing use of novel antiplatelet and anticoagulant agents in patients undergoing ambulatory procedures.
• Challenges in managing antithrombotic therapy due to unique properties of new agents.

Purpose of the Study:

• To review the management of antithrombotic therapy in the ambulatory setting for patients on new agents.
• To assess how novel features of these agents impact clinical decision-making.

Main Methods:

• Review of recent literature and guidelines on antithrombotic agent management.
• Emphasis on risk assessment (bleeding vs. thrombotic) and pharmacokinetic properties.

Main Results:

• Limited studies exist on the comparative risks of continuing or ceasing new agents.
• New agents offer benefits but pose challenges in monitoring and reversal.
• Assessment of procedural bleeding risk, thrombotic risk, and patient-specific factors is crucial.

Conclusions:

• Clinical decisions require a multidisciplinary approach, balancing thrombotic and bleeding risks.
• Knowledge of drug pharmacokinetics is essential for rational management.
• Individualized patient assessment is key when managing antithrombotic therapy perioperatively.